Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neuroblastoma 5Recurrence 2Multiple Myeloma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Transplant-Related Hematologic Malignancy 1Stomatitis 1Oligodendroglioma 1Neoplasms 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Carcinoma, Intraductal, Noninfiltrating 1Brain Neoplasms 1

Interventions

tebentafusp 4Nivolumab 4Magnetic Resonance Spectroscopy 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2cemiplimab 2Specimen Handling 2Ipilimumab 2Interleukin-2 2sargramostim 1quisinostat 1olaparib 1lifileucel 1binimetinib 1aldesleukin 1aflibercept 1Valproic Acid 1Spinal Puncture 1Protein Kinase C 1Melatonin 1Interleukin-13 1Hematologic Tests 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Exercise 1Crizotinib 1Carmustine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uveal Melanoma × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Thomas Jefferson University

Phase 1/2 Recruiting
109 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡